A Trial of Axitinib/Nivolumab Combination Therapy vs Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma Across All Age Groups

About this Study

The purpose of this study is to learn more about how to treat translocation renal cell carcinoma (tRCC), and to find out what effects, good and/or bad, axinitib and nivolumab have on participants when the drugs are given alone or in combination.

Sponsor Protocol ID:AREN1721
IRB Number:2019-0015
Actively Enrolling
Interventional
Phase 2
May 28, 2019
Eligibility Criteria
Both Male and Female
Yes
Yes
No

Inclusion CriteriaThis study is designed to study patients with histologically confirmed, unresectable or metastatic translocation morphology renal cell carcinoma diagnosed using WHO-defined criteria who also have measurable disease as defined by RECIST v1.1 and an inability to undergo complete resection of the disease by surgery.
Therefore, patients eligible for this study must have histological confirmation of disease either by biopsy, nephrectomy or metastectomy and after this diagnostic surgery still have remaining, measurable disease. The decision about the resectability of remaining disease is left to the treating institution.

Exclusion Criteria

  • Patients unable to swallow whole tablets.
  • Patients who in the opinion of the investigator are not able to comply with the study procedures are not eligible. 
  • Prior Therapy
  1. Patients may not be receiving any other investigational agents
  2. (within 4 weeks prior to study enrollment).
  3. Surgery: Patients who have had or who are planning to have the
  4. following invasive procedures are not eligible: Major surgical procedure, laparoscopic procedure, open biopsy, core biopsy, fine needle aspirate, or significant traumatic injury within 7 days prior to enrollment.

Categories Click category to view its trials.
Cancer
Participating Locations
Children’s of Mississippi Hospital - Blair E. Batson Tower
Contact Information
Contact Name: Maggie Goad
Phone Number: 601-815-9390
Email: mgoad@umc.edu
Principal Investigator:Betty H Melton
How to participate in our Clinical Trials